VLS Valneva SE

VALNEVA Declaration of shares and voting rights - November 30, 2023

VALNEVA Declaration of shares and voting rights - November 30, 2023

VALNEVA

Declaration of shares and voting rights

November 30, 2023

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: December 6, 2023

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 138,912,142



ordinary shares with a par value of €0.15 each		162,178,538Double voting rights granted on 569 ordinary shares



 		Between November 4 & November 26, 2023



 		162,054,216

  

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
06/12/2023

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vac...

Valneva Announces FDA’s Decision to Suspend License of Chikungunya Vaccine IXCHIQ® in the U.S. Saint Herblain (France), August 25, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United States Food and Drug Administration (FDA) has suspended the license for IXCHIQ®, citing four new reports of serious adverse events (SAEs) consistent with chikungunya-like illness. The suspension of the license is effective immediately and requires Valneva to stop shipping and selling of IXCHIQ® in the United States. The suspension follows the FDA’s decisio...

August 25, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ...

Valneva annonce la décision de la FDA de suspendre la licence d’IXCHIQ® aux États-Unis Saint Herblain (France), le 25 août, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que l’agence de santé américaine Food and Drug Administration (FDA) a suspendu la licence d’IXCHIQ®, citant quatre nouveaux cas d’effets indésirables graves s’apparentant à la maladie provoquée par le chikungunya. Cette suspension entre en vigueur immédiatement et implique une interruption de l’envoi et de la vente d’IXCHIQ® aux États-Unis. Cette suspension fait su...

August 25, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Ind...

Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in Canada for Individuals Aged 12 and Older Saint Herblain (France), August 18, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has granted marketing authorization for its single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus in individuals aged 12 years and older. This announcement adds to the adult marketing authorization already received in Canada1 and complements the adolescent label extension received in Europe in April 20252. In addit...

August 18, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé ...

Le vaccin IXCHIQ® de Valneva contre le chikungunya désormais autorisé au Canada pour les personnes âgées de 12 ans et plus Saint-Herblain (France), le 18 août 2025 – (Nasdaq : VALN ; Euronext Paris : VLA), société spécialisée dans les vaccins, a annoncé aujourd'hui que Santé Canada a accordé une autorisation de mise sur le marché pour son vaccin à dose unique, IXCHIQ®, pour la prévention de la maladie causée par le virus du chikungunya chez les personnes âgées de 12 ans et plus. Cette annonce s'ajoute à l'autorisation de mise sur le marché déjà obtenue au Canada pour les adultes1 et fait...

August 18, 2025 1 EN
Adrian Pehl
  • Adrian Pehl
SZG SALZGITTER AG
ISS ISS A/S
VLS VALNEVA SE
NOEJ NORMA GROUP SE
ROS ROSENBAUER INTERNATIONAL AG
INH INDUS HOLDING AG
TEG TAG IMMOBILIEN AG
COK CANCOM SE
TECN TECAN GROUP AG
TWEKA TKH GROUP N.V. CERT
JUN3 JUNGHEINRICH AG PREF
JST JOST WERKE AG
DMP DERMAPHARM HOLDING SE
AEIN ALLGEIER HOLDING AG
FQT FREQUENTIS AG WIENER
ALLFG ALLFUNDS (UK) LTD
SCHOTT PHARMA AG
08/12/25 August 12, 2025 1 FR

ResearchPool Subscriptions

Get the most out of your insights

Get in touch